The Auto Channel
The Largest Independent Automotive Research Resource
The Largest Independent Automotive Research Resource
Official Website of the New Car Buyer

Wall Street Media Presents Eric Whitman, MD on Delcath's Positive Clinical Results

NEW YORK--Wall Street Media presents an exclusive video of Dr. Eric Whitman, a highly regarded surgical oncologist who specializes in melanoma and is Director of the Atlantic Melanoma Center. Dr. Whitman attended the American Society of Clinical Oncology’s (ASCO) Annual Meeting, where he took special note of a presentation on Delcath’s  PHP study. Dr. Whitman stresses that PHP has proven to be clinically effective.

“There is no question in my mind that this is clinically effective.”

Please visit the following link to view the video:

Delcath's PHP clinical trials have focused on a certain melanoma spread to the liver.

Some key factors we think were overlooked or misunderstood in today's market action are:

  • Survival rate tripled for cancer patients treated with PHP (Percutaneous Hepatic Perfusion) - 398 days vs. 124 with best alternative care
  • The data was even better than the initial press release from April. The hepatic PFS (primary endpoint) was 245 days in the PHP arm and 49 days in the BAC (best alternative care) arm
  • $745 million is the estimate for peak annual U.S. sales, if PHP is approved by the FDA
  • Potential increase to $5.6 billion if this treatment is used in primary liver cancer as well as metastases from other types of cancer

We discuss the vast potential for Delcath's PHP system:

  • The majority of the cases are not in the US, 80% of liver cancer is in Asia
  • The possibility for huge "off-label" use
  • The possibility for Delcath's PHP system to be used for many other cancer treatments in future

On his blog at Dr. Whitman states "There is no question in my mind that this is clinically effective."

In another recent case of seriously misleading stock information, Todd Sullivan of shares the value he sees in ACAS after their public downgrade.

Please visit the following link to view the video:

Many Biotechs with positive news released today suffered in the general market meltdown. VIVUS Inc. who we also like released positive Phase III data from The Revive Diabetes study for product Avanafil. Nevertheless, their shares dropped $.41 today.

Please visit the following link to view the video:

Follow and learn from Wall Street Media on StockTwits:

Wall Street Media presents exclusive insights from the leading transparent investors on the planet:

After catching up on stock news and making money, visit DateTwit to send a free smile or a virtual drink to anyone on Twitter without blowing your social media capital: